Tuberculosis control in South African gold mines: mathematical modeling of a trial of community-wide isoniazid preventive therapy
- PMID: 25792607
- PMCID: PMC4388015
- DOI: 10.1093/aje/kwu320
Tuberculosis control in South African gold mines: mathematical modeling of a trial of community-wide isoniazid preventive therapy
Abstract
A recent major cluster randomized trial of screening, active disease treatment, and mass isoniazid preventive therapy for 9 months during 2006-2011 among South African gold miners showed reduced individual-level tuberculosis incidence but no detectable population-level impact. We fitted a dynamic mathematical model to trial data and explored 1) factors contributing to the lack of population-level impact, 2) the best-achievable impact if all implementation characteristics were increased to the highest level achieved during the trial ("optimized intervention"), and 3) how tuberculosis might be better controlled with additional interventions (improving diagnostics, reducing treatment delay, providing isoniazid preventive therapy continuously to human immunodeficiency virus-positive people, or scaling up antiretroviral treatment coverage) individually and in combination. We found the following: 1) The model suggests that a small proportion of latent infections among human immunodeficiency virus-positive people were cured, which could have been a key factor explaining the lack of detectable population-level impact. 2) The optimized implementation increased impact by only 10%. 3) Implementing additional interventions individually and in combination led to up to 30% and 75% reductions, respectively, in tuberculosis incidence after 10 years. Tuberculosis control requires a combination prevention approach, including health systems strengthening to minimize treatment delay, improving diagnostics, increased antiretroviral treatment coverage, and effective preventive treatment regimens.
Keywords: mass community-wide isoniazid preventive therapy; mathematical model; tuberculosis.
© The Author 2015. Published by Oxford University Press on behalf of the Johns Hopkins Bloomberg School of Public Health. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com.
Figures






Similar articles
-
A trial of mass isoniazid preventive therapy for tuberculosis control.N Engl J Med. 2014 Jan 23;370(4):301-10. doi: 10.1056/NEJMoa1214289. N Engl J Med. 2014. PMID: 24450889 Clinical Trial.
-
Effect of routine isoniazid preventive therapy on tuberculosis incidence among HIV-infected men in South Africa: a novel randomized incremental recruitment study.JAMA. 2005 Jun 8;293(22):2719-25. doi: 10.1001/jama.293.22.2719. JAMA. 2005. PMID: 15941800 Clinical Trial.
-
The timing of tuberculosis after isoniazid preventive therapy among gold miners in South Africa: a prospective cohort study.BMC Med. 2016 Mar 23;14:45. doi: 10.1186/s12916-016-0589-3. BMC Med. 2016. PMID: 27004413 Free PMC article.
-
Tuberculosis preventive therapy: an underutilised strategy to reduce individual risk of TB and contribute to TB control.S Afr Med J. 2014 Apr 16;104(5):339-43. doi: 10.7196/samj.8290. S Afr Med J. 2014. PMID: 25212199 Review.
-
Scale-up of isoniazid preventive therapy in PEPFAR-assisted clinical sites in South Africa.Int J Tuberc Lung Dis. 2012 Aug;16(8):1020-2. doi: 10.5588/ijtld.11.0744. Epub 2012 Jun 5. Int J Tuberc Lung Dis. 2012. PMID: 22668595 Review.
Cited by
-
Lansoprazole use and tuberculosis incidence in the United Kingdom Clinical Practice Research Datalink: A population based cohort.PLoS Med. 2017 Nov 21;14(11):e1002457. doi: 10.1371/journal.pmed.1002457. eCollection 2017 Nov. PLoS Med. 2017. PMID: 29161254 Free PMC article. Clinical Trial.
-
Durations of asymptomatic, symptomatic, and care-seeking phases of tuberculosis disease with a Bayesian analysis of prevalence survey and notification data.BMC Med. 2021 Nov 10;19(1):298. doi: 10.1186/s12916-021-02128-9. BMC Med. 2021. PMID: 34753468 Free PMC article.
-
Tuberculosis Infectiousness and Host Susceptibility.J Infect Dis. 2017 Nov 3;216(suppl_6):S636-S643. doi: 10.1093/infdis/jix361. J Infect Dis. 2017. PMID: 29112746 Free PMC article. Review.
-
Economic and modeling evidence for tuberculosis preventive therapy among people living with HIV: A systematic review and meta-analysis.PLoS Med. 2021 Sep 14;18(9):e1003712. doi: 10.1371/journal.pmed.1003712. eCollection 2021 Sep. PLoS Med. 2021. PMID: 34520463 Free PMC article.
-
A proposed novel framework for monitoring and evaluation of the cascade of HIV-associated TB care at the health facility level.J Int AIDS Soc. 2017 Apr 20;20(1):21375. doi: 10.7448/IAS.20.01.21375. J Int AIDS Soc. 2017. PMID: 28440604 Free PMC article.
References
-
- World Health Organization. Global Tuberculosis Report, 2012. Geneva, Switzerland: World Health Organization; 2012.
-
- van Halsema CL, Fielding KL, Chihota VN, et al. Trends in drug-resistant tuberculosis in a gold-mining workforce in South Africa, 2002–2008. Int J Tuberc Lung Dis. 2012;167:967–973. - PubMed
-
- Ferebee SH. Controlled chemoprophylaxis trials in tuberculosis. A general review. Bibl Tuberc. 1970;26:28–106. - PubMed
-
- Fielding KL, Grant AD, Hayes RJ, et al. Thibela TB: design and methods of a cluster randomised trial of the effect of community-wide isoniazid preventive therapy on tuberculosis amongst gold miners in South Africa. Contemp Clin Trials. 2011;323:382–392. - PubMed
-
- Churchyard GJ, Fielding KL, Lewis JJ, et al. A trial of mass isoniazid preventive therapy for tuberculosis control. N Engl J Med. 2014;3704:301–310. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical